IN8bio, Inc.

IN8bio, Inc. reported a net loss of $19.4 million for fiscal year 2025, an improvement from a net loss of $30.4 million in the prior year. The company generated no revenue, consistent with its clinical-stage status. The reduced loss was driven by a significant decrease in total operating expenses to $19.9 million from $30.7 million in 2024, primarily due to pipeline prioritization and a 49% workforce reduction implemented in September 2024. Research and development expenses decreased to $10.2 million from $17.0 million, while general and administrative expenses fell to $9.7 million from $12.6 million. The company ended the year with $27.1 million in cash, which management states is expected to fund operations through April 2027, though substantial doubt about the company's ability to continue as a going concern remains. Cash flow from financing activities provided $28.6 million, mainly from a $18.5 million private placement and $8.6 million from an ATM program.

Key Takeaways